2seventy Bio Stock Today
| TSVT Stock | USD 4.95 2.15 76.79% |
PerformanceOK
| Odds Of DistressHigh
|
2Seventy Bio is selling for under 4.95 as of the 17th of March 2025; that is 76.79 percent increase since the beginning of the trading day. The stock's last reported lowest price was 4.94. 2Seventy Bio has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of November 2021 | Category Healthcare | Classification Health Care |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 52.3 M outstanding shares of which 5.14 M shares are at this time shorted by private and institutional investors with about 17.13 trading days to cover. More on 2Seventy Bio
Moving against 2Seventy Stock
2Seventy Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Director | Nick Leschly | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Levels2Seventy Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 2Seventy Bio's financial leverage. It provides some insight into what part of 2Seventy Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2Seventy Bio (TSVT) is traded on NASDAQ Exchange in USA. It is located in 60 Binney Street, Cambridge, MA, United States, 02142 and employs 274 people. 2Seventy Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 258.88 M. 2Seventy Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 52.3 M outstanding shares of which 5.14 M shares are at this time shorted by private and institutional investors with about 17.13 trading days to cover.
2Seventy Bio currently holds about 357.93 M in cash with (166.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check 2Seventy Bio Probability Of Bankruptcy
Ownership Allocation2Seventy Bio holds a total of 52.3 Million outstanding shares. The majority of 2Seventy Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 2Seventy Bio to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in 2Seventy Bio. Please pay attention to any change in the institutional holdings of 2Seventy Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check 2Seventy Ownership Details
2Seventy Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 1.1 M | |
| Eversept Partners, Llc | 2024-12-31 | 1 M | |
| Cowen And Company, Llc | 2024-09-30 | 800 K | |
| The Toronto-dominion Bank | 2024-12-31 | 800 K | |
| Western Standard Llc | 2024-12-31 | 788.4 K | |
| Engine Capital Management Lp | 2024-12-31 | 704 K | |
| Madison Avenue Partners, Lp | 2024-12-31 | 579.9 K | |
| Venator Management Llc | 2024-12-31 | 575 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 482.2 K | |
| Kynam Capital Management, Lp | 2024-12-31 | 6 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 4.3 M |
2Seventy Bio Historical Income Statement
2Seventy Stock Against Markets
2Seventy Bio Corporate Management
| Teresa JD | General VP | Profile | |
| Susan AbuAbsi | Chief Officer | Profile | |
| DPHIL Phil | Chief Officer | Profile | |
| Anna TruppelHartmann | Chief Officer | Profile | |
| Victoria Eatwell | Chief Officer | Profile | |
| Steven Shamah | Head Research | Profile |
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.